Euroimmun, a German medical laboratory-diagnostics firm, has placed a Scienion sciFlexarrayer arraying platform in its lab to help it develop multiplexed diagnostics and produce new tests, Scienion said this week.
The deal, financial terms of which were undisclosed, fits with Scienion's strategy of placing its arrayer instruments with diagnostic partners for use in test manufacturing.
Scienion CEO Holger Eickhoff said in a statement that Euroimmun will "benefit" from using the company's technology and stimulate "further growth" in the in vitro diagnostics market.
Headquartered in Lübeck, Germany, Euroimmun produces reagents for use in medical labs. The firm has focused on tests for antibodies in patient serum that indicate the presence of autoimmune diseases, infectious diseases, and allergies.
Ulf Steller, head of Euroimmun's microarray division, said because his company manufactures different types of diagnostic tests, a "key advantage" of Scienion's arrayer is its "flexibility" in printing DNA, proteins, and other biomolecules.
Steller also noted that Euroimmun can scale up to higher-throughput Scienion systems as its production needs increase.
Scienion currently sells six sciFlexarrayer instruments: The entry-level model DW, which can produce four arrays in one run; the S3, which is used only for R&D applications; the S5 and S11, which enables medium-throughput array manufacturing; the S100, which can produce over 1,000 arrays per run for high-throughput manufacturing; and the compact SX system, which includes components from all of Scienion's arrayers in one enclosure.
"We expect that the integration of Scienion’s scalable technology will help us adapt production processes to the throughput we need in the [coming] years," Steller said.
Eickhoff said he expects Scienion will ink similar deals soon. For instance, the firm recently began manufacturing tests for Genomica, a Madrid-based molecular-diagnostics shop (BAN 2/8/2011).
"Dispensing and depositing reagents in the picoliter to nanoliter range has become crucial for next-generation diagnostic products," Eickhoff said. "Scienion is well-positioned to enable the dispensing of any kind of content to any kind of surface and this is a strategic advantage for the continuously growing market of multiplexed assays in the [IVD] field."
Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.